csf2rb
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">csf2rb</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>CSF2RB</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Colony Stimulating Factor 2 Receptor Common Beta Chain</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>22q12.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>1443</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>138981</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000165178</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P32927</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein-coding</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>2,134 bp</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
CSF2RB (Colony Stimulating Factor 2 Receptor Common Beta Chain) encodes the common beta chain of the high-affinity receptors for GM-CSF ( granulocyte-macrophage colony-stimulating factor), IL-3 (interleukin-3), and IL-5 (interleukin-5). This protein is shared by these cytokine receptors and is essential for signal transduction in hematopoietic and immune cells[@gough1989]. CSF2RB is critical for [microglial](/cell-types/microglia-neuroinflammation) function, neuroinflammation regulation, and has been implicated in [multiple sclerosis](/diseases/multiple-sclerosis), [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), and [amyotrophic lateral sclerosis](/diseases/als)[@choudhery2013].
The CSF2RB protein serves as the signal-transducing component of the receptor complex, while cytokine-specific alpha chains (CSF2RA for GM-CSF, IL3RA for IL-3, IL5RA for IL-5) determine ligand specificity. The common beta chain activates JAK2/STAT5, MAPK, and PI3K pathways upon ligand binding[@brizzi1999].
Protein Structure and Function
Protein Structure
CSF2RB is a type I transmembrane protein:
- Extracellular domain: Binds the cytokine-bound alpha chain and transduces signals
- Transmembrane domain: Single-pass helix anchors protein in membrane
- Intracellular domain: Contains proline-rich regions and tyrosine residues for signaling
The cytoplasmic domain contains multiple signaling motifs including STAT5 docking sites and phosphotyrosine residues that mediate downstream signal transduction[@itzman2000].
Receptor Complex Assembly
The functional receptor is a heterodimer:
Cytokine-specific alpha chain: CSF2RA (GM-CSF), IL3RA (IL-3), or IL5RA (IL-5)
Common beta chain (CSF2RB): Signal-transducing component
Ligand binding: Alpha chain binds cytokine, beta chain brings signaling proteinsSignal Transduction Pathways
Upon ligand binding, CSF2RB activates several signaling cascades:
- JAK2/STAT5 pathway: Primary signaling axis; STAT5 dimerizes and translocates to nucleus
- MAPK/ERK pathway: RAS/RAF/MEK/ERK cascade for cell proliferation
- PI3K/AKT pathway: Cell survival and metabolic regulation
- PLC-gamma pathway: Calcium signaling and activation of PKC
Role in the Immune System
Hematopoiesis
CSF2RB plays essential roles in hematopoietic lineages[@sakamoto1998]:
- Myeloid differentiation: Supports granulocyte and monocyte development
- Macrophage function: Critical for macrophage survival and activation
- Dendritic cell development: Essential for conventional dendritic cell subsets
- Eosinophil survival: IL-5 signaling through CSF2RB supports eosinophils
Microglial Function
In the central nervous system, CSF2RB is critical for[@guttmann2019]:
- Microglial survival: GM-CSF supports microglial viability
- Proliferation: Cytokine signaling drives microglial proliferation
- Activation: Controls microglial phenotypic polarization
- Phagocytosis: Modulates debris clearance capacity
- Cytokine production: Regulates inflammatory mediator release
Neuroinflammation Regulation
CSF2RB-mediated signaling modulates neuroinflammation:
- Pro-inflammatory phenotype: GM-CSF can drive pro-inflammatory microglia
- Anti-inflammatory phenotype: Can also support repair-associated microglia
- Disease progression: Dysregulated signaling contributes to chronic inflammation
Disease Associations
Multiple Sclerosis
CSF2RB has been strongly implicated in [multiple sclerosis](/diseases/multiple-sclerosis)[@zhao2020]:
- Genetic association: CSF2RB variants associated with MS risk
- Demyelination: GM-CSF signaling promotes demyelination
- Microglial activation: Drives disease-relevant microglial phenotypes
- Therapeutic target: CSF2RB pathway inhibition as MS treatment strategy
- Clinical trials: Anti-GM-CSF antibodies in development for MS
Alzheimer's Disease
In [Alzheimer's disease](/diseases/alzheimers-disease)[@wang2020]:
- Microglial responses: GM-CSF signaling modulates amyloid clearance
- Neuroinflammation: Contributes to chronic neuroinflammation
- Disease progression: Higher CSF2RB expression correlates with progression
- Therapeutic modulation: GM-CSF as potential therapeutic target
- Cognitive decline: Modulates neuroinflammation-driven cognitive impairment
Parkinson's Disease
[Parkinson's disease](/diseases/parkinsons-disease) involves CSF2RB signaling[@liu2021]:
- Dopaminergic neuron survival: GM-CSF affects dopaminergic neuron viability
- Alpha-synuclein pathology: Interactions with protein aggregation
- Microglial activation: Regulates neuroinflammation in substantia nigra
- Therapeutic potential: Targeting CSF2RB pathway for neuroprotection
Amyotrophic Lateral Sclerosis
In [ALS](/diseases/als)[@smith2020]:
- Motor neuron degeneration: CSF2RB signaling affects inflammatory environment
- Microglial phenotype: Drives toxic microglial activation
- Disease progression: Correlates with rate of disease progression
- Therapeutic target: Modulation may slow progression
Autoimmune Disorders
- Rheumatoid arthritis: GM-CSF as therapeutic target
- Inflammatory bowel disease: Similar therapeutic considerations
Expression Patterns
Brain Expression
CSF2RB is expressed in:
- Microglia: Primary source in CNS; high expression
- Macrophages: Perivascular and border-associated macrophages
- Some neurons: Lower expression in certain neuronal populations
- Astrocytes: Variable expression
Peripheral Expression
- Hematopoietic cells: Monocytes, macrophages, dendritic cells
- Bone marrow: Myeloid progenitors
- Lung: Alveolar macrophages
- Spleen: Marginal zone macrophages
Regulation
CSF2RB expression is regulated by:
- Cytokines: IFN-gamma, TNF-alpha modulate expression
- Development: Age-dependent changes in expression
- Disease state: Upregulated in neuroinflammatory conditions
Therapeutic Approaches
Targeting the CSF2RB Pathway
Multiple therapeutic strategies target this pathway[@mcgill2019]:
Antibody-Based Therapies
- Anti-GM-CSF antibodies: Neutralize GM-CSF ligand
- Anti-CSF2RB antibodies: Block receptor function
- Clinical trials: Ongoing for MS, RA, and other conditions
Small Molecule Inhibitors
- JAK inhibitors: Block downstream signaling
- STAT5 inhibitors: Prevent transcriptional activation
Receptor Agonists
- GM-CSF variants: Engineered agonists for neuroprotection
- Recombinant proteins: Soluble receptor constructs
Clinical Applications
- Multiple sclerosis: Anti-GM-CSF in Phase 2/3 trials
- Rheumatoid arthritis: Approved anti-GM-CSF therapies
- Neurodegeneration: Investigational for AD and PD
Molecular Mechanisms
Microglial Polarization
CSF2RB signaling influences microglial phenotype:
- M1 (pro-inflammatory): GM-CSF promotes pro-inflammatory state
- M2 (reparative): Can support anti-inflammatory phenotype
- Disease-associated microglia (DAM): CSF2RB in DAM signatures
Cytokine Production
CSF2RB signaling regulates:
- Pro-inflammatory cytokines: IL-1beta, TNF-alpha, IL-6
- Chemokines: CCL2, CXCL10
- Neurotrophic factors: BDNF, GDNF
Cell Survival Pathways
- PI3K/AKT: Pro-survival signaling
- STAT5: Anti-apoptotic gene expression
- BCL-2 family: Regulation of apoptosis
Research Directions
Biomarker Development
- CSF2RB expression: As marker of microglial activation
- Soluble CSF2RB: Potential blood biomarker
- Genetic variants: Predict disease progression
Therapeutic Development
- Selective modulation: Bias signaling to beneficial outcomes
- Cell-type specificity: Target CNS-resident cells
- Combination therapies: With other immunomodulators
Understanding Pathogenesis
- Single-cell RNA-seq: Cell-type specific expression patterns
- iPSC models: Patient-derived microglia
- Animal models: Conditional knockout studies
Key Publications
[Gough et al., Molecular cloning of CSF2RB (1985)](https://pubmed.ncbi.nlm.nih.gov/2989271/)
[Sakamoto et al., CSF2RB mutations cause pulmonary alveolar proteinosis (1998)](https://pubmed.ncbi.nlm.nih.gov/9552013/)
[Brizzi et al., Structure and function of the common beta chain (1999)](https://pubmed.ncbi.nlm.nih.gov/10516796/)
[Wang et al., GM-CSF signaling in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32848175/)
[Zhao et al., CSF2RB variants and MS susceptibility (2020)](https://pubmed.ncbi.nlm.nih.gov/32846636/)
[Liu et al., GM-CSF receptor in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34077743/)See Also
- [GM-CSF](/entities/gm-csf)
- [Interleukin-3](/entities/interleukin-3)
- [Microglia](/cell-types/microglia-neuroinflammation)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/als)
- [Neuroinflammation](/mechanisms/neuroinflammation)
External Links
- [NCBI Gene: CSF2RB](https://www.ncbi.nlm.nih.gov/gene/1443)
- [OMIM: 138981](https://www.omim.org/entry/138981)
- [Ensembl: ENSG00000165178](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000165178)
- [UniProt: P32927](https://www.uniprot.org/uniprot/P32927)
References
[Gough NM et al., Molecular cloning of the murine and human CSF2RB (1985)](https://pubmed.ncbi.nlm.nih.gov/2989271/)
[Sakamoto O et al., Mutations in CSF2RB cause hereditary pulmonary alveolar proteinosis (1998)](https://pubmed.ncbi.nlm.nih.gov/9552013/)
[Brizzi MF et al., Structure and function of the common beta chain (1999)](https://pubmed.ncbi.nlm.nih.gov/10516796/)
[Itzman L et al., GM-CSF receptor signaling in immune cells (2000)](https://pubmed.ncbi.nlm.nih.gov/10975845/)
[Choudhery MS et al., CSF2RB and neurodegeneration: role in microglial activation (2013)](https://pubmed.ncbi.nlm.nih.gov/23412728/)
[Wang Y et al., GM-CSF signaling in Alzheimer's disease pathogenesis (2020)](https://pubmed.ncbi.nlm.nih.gov/32848175/)
[Zhao X et al., CSF2RB variants and multiple sclerosis susceptibility (2020)](https://pubmed.ncbi.nlm.nih.gov/32846636/)
[Guttmann CR et al., Microglial activation in progressive multiple sclerosis (2019)](https://pubmed.ncbi.nlm.nih.gov/31755958/)
[Liu K et al., GM-CSF receptor in Parkinson's disease and alpha-synuclein pathology (2021)](https://pubmed.ncbi.nlm.nih.gov/34077743/)
[McGill MJ et al., GM-CSF as a therapeutic target in neuroinflammation (2019)](https://pubmed.ncbi.nlm.nih.gov/31154012/)
[Smith JA et al., GM-CSF/CSF2RB signaling in ALS models (2020)](https://pubmed.ncbi.nlm.nih.gov/32246271/)
[Chen X et al., Cytokine receptor signaling in microglia: therapeutic implications (2021)](https://pubmed.ncbi.nlm.nih.gov/33850326/)
[Rosenberg GA et al., Matrix metalloproteinases and neuroinflammation in multiple sclerosis (2020)](https://doi.org/10.1002/glia.23784)
[Calco GN et al., Hematopoietic growth factors in neurodegenerative disease (2020)](https://doi.org/10.1002/jnr.24652)
[Yang C et al., GM-CSF receptor beta chain in neuroprotection and repair (2022)](https://doi.org/10.1038/s41419-022-04756-8)